Today: 8 November 2025
Subscribe
Browse Tag

Healthcare

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Pops as White House Strikes Obesity-Drug Pricing Deal; New 20% Weight‑Loss Data Fuels Momentum — Today, November 6, 2025

Eli Lilly stock today: drivers, numbers, and what to watch for next. Key takeaways (Nov 6, 2025) Eli Lilly stock today: quote & range As of this afternoon, LLY traded near $935.89, up about 1.1%, with today’s range $916.37–$949.90 and a 52‑week range $624.00–$955.43 (values delayed up to 15 minutes). Reuters 1) The White House’s obesity‑drug deal: lower prices, broader access President Donald Trump announced deals with Eli Lilly and Novo Nordisk to reduce U.S. costs and expand coverage for in‑demand weight‑loss medicines. The plan includes Medicare coverage for obesity treatment, expected to carry $50 monthly copays for eligible beneficiaries,
6 November 2025
 ·  ·  ·  ·  ·  · 
Telehealth Trailblazer VSee Health (VSEE) Skyrockets on Game-Changing Deals & Federal Green Light

Telehealth Trailblazer VSee Health (VSEE) Skyrockets on Game-Changing Deals & Federal Green Light

Company Overview: Telehealth for High-Acuity Care VSee Health, Inc. is a Silicon Valley-founded telehealth technology and services provider specializing in high-acuity virtual care. Founded in 2008 by Dr. Milton Chen, VSee built a secure video telemedicine platform so robust it was even utilized by NASA for astronaut healthcare businesswire.com. Today, after merging with iDoc Telehealth via a SPAC deal in mid-2024, VSee offers an integrated suite of telehealth solutions for hospitals and health systems. The company’s headquarters are in Massachusetts, and it has ~154 employees as of 2025 finviz.com. Business Model: VSee’s platform combines telehealth software with physician services to
4 November 2025
 ·  ·  ·  ·  · 
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers (HIMS) Stock Soars on Subscriber Surge and GLP-1 Deal Buzz – Nov 2025 Update

Current Stock Price (Nov 3, 2025) Hims & Hers Health’s stock (NYSE: HIMS) closed on Nov 3, 2025 at $44.39, down about 2.3% for the day stockanalysis.com. This modest dip came amid a broader mixed market and ahead of the company’s earnings release after the bell. However, immediately following its Q3 earnings report that evening, HIMS shares jumped roughly 6% in after-hours trading, climbing to around $46.70 investing.com. The post-market pop was driven by upbeat revenue and subscriber numbers (more on that below), signaling renewed investor optimism. Even after recent volatility, HIMS stock has had a stellar year. At ~$44–$47,
4 November 2025
 ·  ·  ·  ·  · 
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net income simplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027 tipranks.com, and free cash flow turning positive in 2025 simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation (HIMS trades near ~$45 with market cap in the billions) and regulatory/legal risks. Community “fair value” estimates vary widely (some as low as $41) due to uncertainty simplywall.st. Key
3 November 2025
 ·  ·  ·  ·  · 
DexCom Stock Plunge Raises Big Questions – Will This Diabetes Tech Leader Rebound?

DexCom Stock Plunge Raises Big Questions – Will This Diabetes Tech Leader Rebound?

Latest News: Earnings Beat Marred by Growth Jitters DexCom’s Q3 2025 earnings (reported Oct. 30) were better than expected, but the celebration was short-lived. The headline numbers were strong – $1.209 B revenue (+22% YoY) and $0.61 adjusted EPS – beating consensus on both investing.com. In fact, demand for DexCom’s G7 continuous glucose monitors (CGMs) drove 20% organic growth globally, with U.S. sales up 21% and international up 18% YoY investing.com. Off the back of this strength, management raised full-year 2025 guidance, now targeting ~$4.63 B revenue (~15% growth) investors.dexcom.com and improved operating margins around 20–21%. However, on the earnings call DexCom’s
31 October 2025
 ·  ·  ·  ·  · 
Baxter Stock Plummets 15% After Mixed Q3 Earnings – What Investors Should Know

Baxter Stock Plummets 15% After Mixed Q3 Earnings – What Investors Should Know

Mixed Third-Quarter Financial Results Baxter’s Q3 showed a mixed picture. Revenue from continuing operations rose about 5% year-over-year to $2.84 billion, helped by strong performance in its Pharmaceuticals and Healthcare Systems units baxter.com baxter.com. However, sales fell short of the street’s ~$2.88 billion estimate reuters.com. On profit, Baxter earned an adjusted $0.69 per share, well above the ~$0.60 expected reuters.com chartmill.com. (GAAP results showed a small net loss as some one-time costs were excluded from the adjusted figure baxter.com.) Despite the earnings beat, investors focused on the revenue miss. The stock tumbled ~15% in early trading on Oct. 30, 2025 reuters.com chartmill.com.
30 October 2025
 ·  ·  ·  ·  · 
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Strong Q3 Earnings Propel Stock Higher Guardant’s latest quarterly report blew past Wall Street’s expectations, sparking a sharp rally in its shares. For Q3 2025, revenue was $265.2 million, a 39% jump from a year ago and well above the ~$235 million analysts had forecast investing.com. On an adjusted basis, Guardant lost $0.39 per share, much better than the roughly $0.79 loss expected. Management immediately lifted the full-year sales outlook to $965–970 million (about 31% growth) investors.guardanthealth.com, up from $915–925M previously. As a result, GH stock jumped nearly 30% in morning trading on Oct. 30 (to about $94, from ~$72
30 October 2025
 ·  ·  ·  ·  · 
Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

CI Stock Price and Recent Trend Cigna’s stock has pulled back modestly in late October after a strong run earlier in the year. According to market data, CI closed at $299.12 on Oct 29, 2025, down about 3% from the previous close stockanalysis.com. The dip followed weakness in broader managed-care stocks amid concerns about healthcare costs and policy. In pre-market trading Oct 30, CI rebounded to about $303 (up ~1.3%) reuters.com. Over the past year, CI shares have traded between roughly $257 and $350 stockanalysis.com, reflecting volatility in the insurance sector. Despite the pullback, Cigna’s valuation metrics remain attractive: at
30 October 2025
 ·  ·  ·  · 
VSee Health (VSEE) Stock Rockets 75% on $10M Hospital Teleradiology Deal – Is This Telehealth’s Next Big Winner?

VSee Health Stock Skyrockets 250% on FedRAMP Approval – Will the Rally Last?

Stock Price Surge and Recent Performance VSee Health’s stock has delivered a stunning short-term rally. After closing at just $0.62 per share on Oct. 27, VSEE opened Oct. 28 with a bang – soaring well above $1.50 within hours and briefly touching $2.52 intraday indexbox.io. By afternoon, shares were still up around 200% on the day, trading in the $1.80–$2.00 range. The one-day gain is remarkable for any stock, especially a small-cap telehealth firm. Even after pulling back to a ~$1.91 close, VSEE had more than tripled in value in a single session indexbox.io. This explosive jump follows a week
28 October 2025
 ·  ·  ·  ·  · 
From Cannabis Clinics to Bitcoin Billions: KindlyMD (NAKA) Stock’s Wild 2025 Ride

From Cannabis Clinics to Bitcoin Billions: KindlyMD (NAKA) Stock’s Wild 2025 Ride

Market Analysis & Forecast: For now, analysts and investors appear in “wait and see” mode. Near-term catalysts will be pivotal. These include the finalization (or not) of the Antalpha $250M convertible deal – which would inject capital but on what terms? – and the company’s next earnings report (to show if core healthcare revenue is growing or still minuscule). If Bitcoin’s price continues to climb in late 2025, it could boost KindlyMD’s asset value and perhaps its stock; conversely, a crypto downturn or interest rate spike could hurt both the value of its BTC and its ability to raise funds
28 October 2025
 ·  ·  ·  · 
WGRX Stock Soars on Blockchain Deal as Wellgistics Health Eyes Pharma Disruption

WGRX Stock Soars on Blockchain Deal as Wellgistics Health Eyes Pharma Disruption

Stock Price Rally Powered by Tech Tie-Up Wellgistics Health’s stock price is on a tear after embracing blockchain technology. The tiny healthcare logistics firm saw its shares surge from about $0.40 to the mid-$0.70s overnight on news of a cutting-edge partnership. In after-hours trading late Thursday, WGRX jumped 87.9%, nearly doubling in value benzinga.com. The stock is now trading around $0.73–$0.76 in pre-market action Friday morning stockanalysis.com – a dramatic move for a company that just days ago was flirting with all-time lows. This spike came on the heels of positive news: Wellgistics announced it signed a letter of intent
24 October 2025
 ·  ·  ·  · 
Intuitive Surgical Stock Rockets 17% After Blowout Q3 Earnings – Is $600 Next?

Intuitive Surgical Stock Rockets 17% After Blowout Q3 Earnings – Is $600 Next?

Intuitive Surgical’s da Vinci surgical robot in an operating room setting. Intuitive’s stock jumped on Oct. 21 after the company reported blowout Q3 results and raised full-year guidance reuters.com ts2.tech. The quarter’s 23% revenue growth was driven by a surge in robot-assisted procedures, as hospitals resume elective surgeries and expand minimally-invasive care reuters.com reuters.com. Reuters notes Intuitive has seen “steady growth as hospitals work through a backlog of deferred procedures” reuters.com, reflecting post-pandemic catch-up demand. Intuitive’s CEO Dave Rosa celebrated the results. He noted “continued growth in customer use and adoption of our Ion and da Vinci platforms, including da
22 October 2025
 ·  ·  ·  ·  · 
1 2 3
Go toTop